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lycogen synthase kinase (GSK)-3 is a serine/threonine
kinase that has been implicated in several aspects in
embryonic development and several growth factor
signaling cascades. We now report that an inactive phos-
phorylated pool of the enzyme colocalizes with F-actin in
both neuronal and nonneuronal cells. Semaphorin 3A
(Sema 3A), a molecule that inhibits axonal growth, activates
GSK-3 at the leading edge of neuronal growth cones and in
Sema 3A–responsive human breast cancer cells, suggesting
G
 
that GSK-3 activity might play a role in coupling Sema
3A signaling to changes in cell motility. We show that
three different GSK-3 antagonists (LiCl, SB-216763, and
SB-415286) can inhibit the growth cone collapse response
induced by Sema 3A. These studies reveal a novel compart-
mentalization of inactive GSK-3 in cells and demonstrate for
the ﬁrst time a requirement for GSK-3 activity in the Sema
3A signal transduction pathway.
 
Introduction
 
Axonal pathfinding is mediated by a specialized structure at
the leading tip of an extending axon, the growth cone,
which is able to recognize guidance cues and translate this
information into directed motility. Depending on their nature,
guidance cues can either stabilize or destabilize discrete areas
of the growth cone. Several signals have been isolated and
based on in vitro and/or in vivo studies characterized as
positive/attractive or inhibitory/repulsive cues (Tessier-Lavigne
and Goodman, 1996). Although we know a considerable
amount concerning the coupling of positive/attractive cues
to a motile response (Doherty et al., 2000), our knowledge
about the signaling cascades that couple the inhibitory cues
to growth cone repulsion remains rudimentary.
Glycogen synthase kinase (GSK)*-3 is an evolutionary
conserved serine/threonine kinase that has been implicated
in several aspects in embryonic development and several
 
growth factor signaling cascades (Siegfried et al., 1992;
 
 
 
He
et al., 1995; Pierce and Kimelman, 1995; Pap and Cooper,
1998). Two genes encode the closely related proteins GSK-3
 
 
 
and GSK-3
 
 
 
, and both forms are widely distributed with
highest levels found in the developing brain (Woodgett, 1990;
Lau et al., 1999). A function for GSK-3 in the establishment
of functional circuits in the nervous system can be postu-
lated based on its developmental expression in axonal
tracts. The steady increase in expression from embryonic
stages to early postnatal development in rat brains with a
decrease in expression at P20 to low levels broadly corre-
lates with the period of axonal extension and dendritic
plasticity (Takahashi et al., 1994, 2000; Leroy and Brion,
1999).
 
Our understanding of the function of GSK-3 in relationship
to axonal growth and guidance is poor and has been limited
by the lack of specific antagonists of the enzyme. In the
present study, we have used phosphospecific antibodies to
reveal the presence of an inactive pool of GSK-3 at the
leading edge of the navigating growth cone and migratory
cells. We have used LiCl and two specific GSK-3 inhibitors
to investigate the function of the enzyme in the growth
cone (Coghlan et al., 2000; Cross et al., 2001). Our results
provide evidence that GSK-3 plays a crucial role in allowing
the growth cone to respond to an inhibitory guidance
cue. We show that after treatment with the inhibitory
guidance molecule Semaphorin 3A (Sema 3A; Luo et al.,
1993) the inactive pool of GSK-3 is rapidly lost from the
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leading edge of the growth cone, and that the three different
GSK-3 antagonists can inhibit the growth cone collapse
response induced by Sema 3A. These studies reveal a
novel compartmentalization of inactive GSK-3 in cells
and demonstrate for the first time a requirement for
GSK-3 activity in the Sema 3A signal transduction pathway.
 
Results and discussion
 
GSK-3 is maintained inactive in association 
with F-actin in different cell types
 
GSK-3 is a unusual protein kinase in that it shows a high
basal activity, and growth factors, including insulin, insulin-
like growth factor, Wnt, and EGF, induce responses in cells
Figure 1. GSK-3 is maintained inactive 
at the leading edge of migratory cells 
and colocalizes with F-actin. Distribution 
of P-(Ser9)-GSK-3  immunoreactivity in 
MDA-MB-231 breast carcinoma cells 
(A, left) and in primary chick fibroblast 
(B, left). A parallel-performed phalloidin 
staining (middle) reveals a great overlap 
of inactive serine-phosphorylated GSK-3 
with F-actin (right, merge). Likewise, in 
DRG growth cones the signals detected 
using an anti–P-(Ser21)-GSK-3  antibody 
(C) and an anti–P-(Ser9)-GSK-3  (D) are 
found colocalized with F-actin in the 
filopodia and at the leading edge of the 
lamellipodia. Stainings performed using 
a pan GSK-3  (E) and a P-(Y)-GSK-3 (F) 
antibody reveal that GSK-3 in present 
throughout the entire growth cone 
structure. Bars, 15  m. (G) Western 
blots probed with indicated P-(Ser)–
specific antibodies: lanes 1 and 3 show 
chick brain lysate, and lanes 2 and 4 
show Cos-7 cell lysate that have been 
transfected with GSK-3  and GSK-3 , 
respectively. 
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by inhibiting the catalytic activity of the enzyme (Saito et al.,
1994; Cook et al., 1996; Eldar-Finkelman et al., 1995;
Waltzer and Bienz, 1999; Ding et al., 2000). Inactivation of
GSK-3 by insulin is achieved by phosphorylation of Ser9
and Ser21 in GSK-3
 
 
 
 and GSK-3
 
 
 
, respectively (Suther-
land et al., 1993; Stambolic and Woodgett, 1994; Cross et
al., 1995), via a mechanism that involves the binding of a
small loop containing the phosphorylated serine back to the
substrate binding site on the enzyme (Frame et al., 2001).
Although not absolutely required for activity, phosphoryla-
tion of a key tyrosine (Tyr279 and Tyr216 in GSK-3
 
 
 
 and
GSK-3
 
 
 
, respectively) enhances activity (Hughes et al.,
1993; Murai et al., 1996), conceivably by increasing sub-
strate access to the enzyme (Dajani et al., 2001).
We have used antibodies that specifically recognize phos-
phorylated Ser9 and phosphorylated Ser21 in GSK-3
 
 
 
 and
GSK-3
 
 
 
 to examine the distribution of the inactive pools of
GSK-3 in cells. In highly migratory MDA-MB-231 breast
cancer cells, an inactive pool of GSK-3
 
 
 
 is found localized at
the leading edge of the cells alongside F-actin (Fig. 1 A).
Likewise, inactive GSK-3
 
 
 
 colocalizes with F-actin in pri-
mary chick fibroblasts (Fig. 1 B). In both cases, inactive
GSK-3
 
 
 
 showed a similar distribution (unpublished data).
In the developing embryo, GSK-3 is highly enriched in the
nervous system. Interestingly, inactive pools of both GSK-
3
 
 
 
 and GSK-3
 
 
 
 are found enriched in the filopodia and at
the leading edge of the lamellipodia of growth cone extend-
ing from an E7 chick dorsal root ganglion (DRG) explants
where they again colocalize with F-actin (Fig. 1, C and D).
These compartmentalizations were apparent in essentially
all growth cones (92 
 
  
 
2.8% and 94.8 
 
  
 
2% of growth
cones for P-GSK-3
 
 
 
 and P-GSK-3
 
 
 
, respectively, 
 
n
 
 
 
  
 
4 ex-
plants, mean 
 
  
 
SEM) and demonstrate that inactive pools of
GSK-3 are preferentially enriched in motile regions of
growth cones and possibly other cells.
The above data might simply reveal differential cellular lo-
calization of the GSK-3 protein per se, or it might reflect dif-
ferential localization of active versus inactive pools of GSK-3.
In neuronal growth cones, the latter appears to be the case,
since antibodies to the protein backbone of GSK-3 or to the
phosphorylated tyrosine residue found in the active enzyme
clearly label growth cones in a uniform manner (Fig. 1, E and
F). The specificity of the P-(Ser21)-GSK-3
 
 
 
 and P-(Ser9)-
GSK-3
 
 
 
 antibodies was confirmed by Western blotting chick
brain lysates and lysates obtained from Cos-7 cells transfected
with GSK-3
 
 
 
 or GSK-3
 
 
 
, and as expected the antibodies de-
tected single bands of 
 
 
 
51 and 47 kD (Fig. 1 G).
The phosphatidylinositol (PI) 3-kinase pathway is one of
the major pathways that inactivates GSK-3 by stimulating a
PKB/Akt-dependent phosphorylation of Ser21 and/or Ser9
(Cross et al., 1995). In primary DRG neurons, treatment
with two selective PI 3-kinase inhibitors (wortmannin and
LY294002) induces a dramatic reduction in the phosphory-
lation of GSK-3
 
 
 
 on Ser21 and GSK-3
 
 
 
 on Ser9 as deter-
mined by Western blotting (Fig. 2 A) and immunocy-
tochemistry (Fig. 2 B). These results demonstrate that under
our culture conditions PI 3-kinase activity is required for in-
activating GSK-3 in the growth cones of primary neurons. It
is also interesting to note that although PI 3-kinase inhibi-
tion by wortmannin does not result in a collapse of the
 
growth cone, it reduces its outspread morphology and ap-
pears to alter the appearance of the actin filaments (Fig. 2 C).
 
Sema 3A activates GSK-3 at the leading edge 
of the growth cone
 
The specific localization of an inactive pool of GSK-3 at the
leading edge of the growth cone suggests a function in the
control of growth cones motility. However it seems highly un-
likely GSK-3 activity is required for responsiveness to guid-
ance cues that promote growth. For example, several factors
that promote axonal growth (e.g., the neurotrophins and the
fibroblast growth factors) do so by activating tyrosine kinase
receptors that have been shown to couple to PI 3-kinase–
dependent pathways (Torres et al., 1999; Hadari et al., 2001;
Huang and Reichardt, 2001; Ong et al., 2001) and would
thereby be expected to inhibit GSK-3 activity. An alternative
possibility is that growth cone responsiveness to inhibitory
guidance cues might depend on GSK-3 activity. Sema 3A is
an inhibitory guidance cue that restricts axonal extension to
permissive areas by demarcating inhibitory territories (Luo et
al., 1993; Messersmith et al., 1995). A “hallmark” of Sema 3A
activity is its ability to induce a very rapid collapse of growth
cones, a response that initially involves depolymerization and/
or redistribution of F-actin at the leading edge of the growth
cone (Fan et al., 1993; Fournier et al., 2000). However, if
growth cones are treated with Sema 3A for a relatively short
Figure 2. Dephosphosphorylation of GSK-3 by inhibition of 
PI 3-kinase. (A) In primary DRG neurons, treatment with wortmannin 
(WM) or LY294002 (LY) at given  M concentrations for 1 h reduces 
the phosphorylation of PKB/AKT and both GSK-3  and GSK-3 . (B) 
Treatment of DRG explant with wortmannin at 0.1  M results in a 
loss of the P-Ser(9)-GSK-3  signal seen in untreated control cultures 
(insert). (C) In a parallel-performed phalloidin staining, the growth 
cone is clearly visible. Bars, 15  m. 
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time (2 min) the redistribution of signaling components
within growth cones can be assessed in the absence of a full
collapse response (Fournier et al., 2000). Treatment with a
Sema 3A–Fc chimera (Eickholt et al., 1997) under these con-
ditions has no obvious effect on the distribution of GSK-3
protein within the partially collapsed growth cones (Fig. 3 A).
In contrast, the short treatment with Sema 3A induces a dra-
matic loss of phosphorylation of both GSK-3
 
 
 
 and GSK-
 
 
 
 at
the periphery of the growth cone (Fig. 3, B and C). Western
blotting using the phospho–GSK-3 antibodies on cell lysates
obtained from untreated primary DRG cultures and Sema
3A–treated cultures revealed that the total level of P–GSK-3
was in some experiments decreased (unpublished data). How-
ever, these results were not robust, and this might be due to
the effects on the small pool of GSK-3 at the leading edge of
the growth cone being masked by little or no change in the
larger pool present in other neuronal compartments includ-
ing, for example, the axon.
Sema 3A can also “collapse” neural crest cells (Eickholt et
al., 1999), and it inhibits the migration of several other cell
types (Miao et al., 1999;
 
 
 
Bagnard et al., 2001). We have ob-
served recently that MDA-MB-231 breast cancer cells show
similar responsiveness to Sema 3A (unpublished data). Since
inactive GSK-3 is found almost exclusively at the leading
edge of these cells (Fig. 1), we reasoned that they might be a
good model for examining the effects of Sema 3A on GSK-3
phosphorylation. In these cells, Western blotting consis-
tently revealed that treatment with Sema 3A (applied for 1 h
at 1 
 
 
 
g/ml) induces a substantial reduction in serine phos-
phorylation on GSK-3
 
 
 
 in the absence of any detectable
change in the level of GSK-3 protein (Fig. 4). As expected,
this activation was not apparent when LiCl was included in
the cultures (20 mM) (Fig. 4). These data not only confirm
that Sema 3A can activate GSK-3, they also extend the ob-
servation to nonneuronal cells.
Figure 3. Sema 3A activates GSK-3 at the leading edge of 
sensory growth cones. DRG cultures grown overnight were 
treated with a Sema 3A–Fc chimera for 2 min before fixation. 
Growth cones were stained with phalloidin–Texas red (left) 
and anti–GSK-3  (A, right) and with phalloidin–Texas red (left) 
and anti–P-(Ser21)-GSK-3  (B, right). After exposure to Sema 3A, 
the entire GSK-3  pool remains homogeneously distributed 
throughout the growth cone and is still detectable in filopodia, 
whereas the inactive P-(Ser21)-GSK-3  is depleted at the leading 
edge of the growth cone and filopodia (arrowheads). The insert 
shows the parallel performed P-(Ser21)-GSK-3  staining in 
untreated control cultures. Bars, 15  m. (C) Percentage of growth 
cones showing enriched staining at the leading edge before and 
after treatment with Sema 3A–Fc. Bars show   SEM.
Figure 4. Decrease in phosphorylation of GSK-3 after Sema 3A 
treatment in MDA-MB-231 breast carcinoma cell lines. Western 
blots of MDA-MB 231 cell extracts using anti–P-(Ser9)-GSK-3 , 
anti–GSK-3 , and antiactin antibodies. Cell lysates were prepared 
from PBS-treated control and Sema 3A–Fc–treated (1  g/ml for 1 h) 
MDA-MB 231 cells in the presence or absence of LiCl (at 20 mM). 
All experiments were performed in duplicates. Sema 3A treatment 
notably decreases Ser9 phosphorylation of GSK-3. Treatment with 
the GSK-3 inhibitor LiCl enhances GSK-3 phosphorylation slightly 
and antagonizes the Sema 3A–mediated decrease in Ser9 phos-
phorylation. Blots were reprobed with an anti–GSK-3  antibody 
to confirm equal loading of samples. 
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In conclusion, before treatment with Sema 3A growth
cones and migratory cells maintain an inactive pool of GSK-3
at their leading edges. Treatment with Sema 3A rapidly ac-
tivates the GSK-3 pool at their leading edge of the growth
cone and substantially activates the total pool of GSK-3 in
migratory cells. These data raise the possibility that this ac-
tivity “switch” of GSK-3 might contribute to the rapid
changes in morphology that are seen in both neuronal and
nonneuronal cells upon exposure to Sema 3A.
 
Inhibition of GSK-3 masks the biological activity 
of Sema 3A
 
A full collapse response to Sema 3A is much more dramatic
than the partial collapse response (Fig. 5). To test whether
GSK-3 activity is required for this response, we tested the ef-
fect of LiCl in the “collapse assay” since it is an established in-
hibitor of both GSK-3
 
 
 
 and GSK-3
 
 
 
 (Stambolic et al., 1996)
and can prevent the Sema 3A activation of GSK-3 (Fig. 4).
Treatment with LiCl at 20 mM had no effect on the basal
level of collapsed growth cones (unpublished data); however,
it inhibited the growth cone collapse response induced by
Sema 3A from 75.3 
 
 
 
 4.1% to 22.7 
 
 
 
 3.2% (
 
n
 
 
 
  
 
8 explants;
Fig. 5, A and B). In control experiments, we found that NaCl
at 20 mM had no effect on the Sema 3A response (78.5 
 
 
 
5.8%, 
 
n 
 
  
 
6). LiCl is not a selective inhibitor of GSK-3 and
has several additional targets (Sherman et al., 1981; Davies et
al., 2000). Therefore, we tested two more specific GSK-3 in-
hibitors for their ability to inhibit the collapse response. SB-
216763 and SB-415286 are structurally distinct maleimides
that are potent inhibitors of GSK-3
 
 
 
 and GSK-3
 
 
 
 in an ATP
competitive manner, and the specificity of these antagonists
has been established in assays against 25 kinases (Coghlan et
al., 2000). In the collapse assay, both compounds were able to
inhibit the biological activity of Sema 3A in a dose-dependent
fashion (Fig. 5) with SB-216763 being more effective than
SB-415286, which correlates with their established efficacy as
GSK-3 inhibitors (Coghlan et al., 2000; Cross et al., 2001).
These data establish that GSK-3 activity is required for the bi-
ological activity of Sema 3A in the collapse assay.
GSK-3 is primarily regarded as an enzyme that is constitu-
tively active in cells with extrinsic agents influencing cell func-
tion via mechanisms that depend on inactivation of the en-
zyme. Here we demonstrate the presence of an inactive pool
of GSK-3 that colocalizes with F-actin at the leading edge in
migratory cells including neurons. The differential distribu-
tion of active and inactive pools of GSK-3 in the neuronal
growth cone suggests a function of the enzyme in the control
of motility events. This notion is supported by our observa-
tion that GSK-3 is activated at the leading edge of growth
cones after treatment with the inhibitory axon guidance mole-
cule Sema 3A and the fact that GSK-3 antagonists inhibit the
growth cone collapse response induced by Sema 3A. How-
ever, activation of GSK-3 by wortmannin does not induce a
growth cone collapse, and this may suggest that although re-
quired, GSK-3 activation is not sufficient to mimic the bio-
logical activity of Sema 3A. At present, several additional sig-
naling molecules have been implicated in the Sema 3A
response, and these include the collapse response mediator
protein (crmp), the small GTPase rac-1, and LIM kinase
(Goshima et al., 1995; Hamajima et al., 1996; Jin and Stritt-
matter, 1997; Kuhn et al., 1999; Vastrik et al., 1999; Aizawa
et al., 2001). It will be of interest to determine if any of these
components can cross talk to GSK-3–dependent pathways.
The “substrates” that couple GSK-3 activity to the growth
cone collapse response are not known. Although it is well es-
tablished that microtubule dynamics are influenced by GSK-3
activity in neurons (Hanger et al., 1992; Mandelkow et al.,
1992; Lovestone et al., 1994; Baum et al., 1995; Sperber et
al., 1995; Garcia-Perez et al., 1998; Goold et al., 1999; Sayas
et al., 1999; Lucas et al., 2001; Sanchez et al., 2001), the rapid
nature of the collapse response together with the established
role of F-actin in this process (Fan et al., 1993; Fritsche et al.,
1999) suggest that this is unlikely to explain our results. In ad-
dition, we also find that stabilization of microtubules with
taxol does not interfere with the rapid collapse response (un-
published data). An alternative possibility is that our findings
reveal a more direct function for GSK-3 in the control of the
actin-based cytoskeleton. It is conceivable that after phosphor-
ylation an as yet to be identified GSK-3 substrate might play a
role in the destabilization and/or rearrangement of F-actin
that accompanies the growth cone collapse response.
The presence of a pool of GSK-3 that is specifically main-
tained in an inactive state leads to the immediate issue as to
Figure 5. Inhibition of GSK-3 prevents Sema 3A–induced growth 
cone collapse. (A) Addition of Sema 3A–Fc to DRG explant cultures 
for 30 min induces a growth collapse response. The graphs show 
the percentage of collapsed growth cone   SEM (n   4 independent 
experiments). In each experiment  100 growth cones were counted. 
In the presence of 20 mM LiCl, the Sema 3A response is substantially 
inhibited, whereas NaCl at 20 mM did not alter the Sema 3A–induced 
growth cone collapse. Likewise, the two specific GSK-3 inhibitors, 
SB-216763 and SB-415286 (used at  M concentrations as stated), 
inhibited the Sema 3A–induced growth cone collapse in a dose-
dependent manner. (B) Examples of phalloidin-stained DRG growth 
cones in order to visualize the distribution of F-actin. First micro-
graph shows a control untreated ( ) growth cone; all subsequent 
pictures show growth cones that have been treated with Sema 3A ( ) 
in the absence (control) and presence of LiCl (20 mM), SB-216763 
(10  M), and SB-415286 (30  M). In the presence of the GSK-3 
antagonist, growth cone collapse is clearly inhibited. Bar, 15  m. 
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how this phosphorylation is controlled. In principle, this
could reflect a relative increase in the activity of the enzymes
that phosphorylate GSK-3 within this region of the growth
cone or a decrease in the activity of phosphatases. It is also
possible that the inactive and active forms of GSK-3 have
different binding partners and that the phosphorylated
GSK-3 might selectively interact with F-actin or an F-actin
binding protein. Our results show that at least in neurons
the inactivation of both GSK-3
 
 
 
 and GSK-3
 
 
 
 is under the
control of the PI 3-kinase pathway. Since an increased activ-
ity of PI 3-kinase at the leading edge in several cell types has
been linked to chemotactic migratory responses (Meili et al.,
1999; Parent and Devreotes, 1999; Servant et al., 2000),
 
inactive GSK-3 may be the common link by which PI
3-kinase keeps the growth cone in a “motile” state.
 
Materials and methods
 
Antibodies and inhibitors
 
Mouse monoclonal anti–GSK-3 (clone 4G-1E) and anti–P-(Y279/216)-
GSK-3 (clone 5G-2F) antibodies were obtained from Upstate Biotechnol-
ogy. Rabbit polyclonal antibody against P-(Ser9)-GSK-3
 
 
 
 was purchased
from Biosource International. Polyclonal sheep antibodies recognizing
GSK-3
 
 
 
 and P-(Ser21)-GSK-3
 
 
 
 (lot 18087) were purchased from Upstate
Biotechnology, and the P-AKT antibody was purchased from Cell Signaling
Technology. The mouse monoclonal antibody against actin was from
Roche. The PI 3-kinase inhibitors LY294002 and wortmannin were pur-
chased from Calbiochem.
 
Cell culture and collapse assays
 
Fertile eggs were obtained from a local supplier (Needle farm). DRG ex-
plants cultures from E7 chick embryos were prepared as described previ-
ously (Eickholt et al., 1997). For immunohistochemistry, DRG explants
 
were plated onto poly-
 
L
 
-Lysine (20 
 
 
 
g/ml)/laminin (20 
 
 
 
g/ml)–coated glass
 
coverslips, and cultures were incubated for 20 h in DME/10% FCS/penicillin/
streptomycin  supplemented with 20 ng/ml NGF before fixation in 4%
paraformaldhyde/10% sucrose. For collapse assays, DRGs were cultured
for 24 h on 20 
 
 
 
g/ml laminin-coated Labtec chamberslides (Nunc). LiCl
(Sigma-Aldrich) and specific GSK-3 inhibitors were applied at given con-
centrations and incubated for 1 h before the Sema 3A–Fc was applied (at 1
 
 
 
g/ml). After 30 min, the cultures were carefully fixed in 4% paraformalde-
hyde/10% sucrose.
 
For cultures of isolated neurons, E7 DRGs were incubated in 1 mg/ml
 
trypsin (Worthington) diluted in Hanks’ buffer for 10 min at 37
 
 
 
C. The trypsin
solution was removed, and explants were triturated in DME/10% FCS using
a fire-polished Pasteur pipette. Isolated cells were preplated in DME/10%
FCS for 2 h on tissue culture plastic in order to enrich for neurons, which
were cultured on laminin (20  g/ml) as before. MDA-MB-231 cells (Ameri-
can Type Culture Collection) were maintained in DME/10% FCS/PenStrep.
Immunocytochemical procedures
PFA-fixed DRG explants were washed twice with PBS, permeablized in
PBS/1% Triton X-100, and blocked in blocking buffer (PBS, 0.5% Triton,
2% BSA). Primary antibody was applied (all antibodies were diluted 1:50
in blocking buffer except anti-P(Y279/216)-GSK-3 antibody that was di-
luted 1:100) and incubated overnight at 4 C with agitation. Bound anti-
body was visualized using FITC-conjugated secondary antibodies (Sigma-
Aldrich; anti–sheep antibody was from Dako). The distribution of F-actin
was visualized using Texas red–conjugated phalloidin (Molecular Probes).
All samples were analyzed using volume deconvolution.
Cell/tissue lysates and Western blot analysis
Cos-7 cells were transfected using Lipofectamine Plus reagents according
to the manufacturer’s protocol. Transfected cells were washed with ice-
cold PBS and lysed in lysis buffer (20 mM Hepes, 150 mM NaCl, 1% Tri-
ton, 5 mM CaCl2, 1 mM MgCl2, protease and phosphatase inhibitors).
Brain lysate from E9 chick brains and lysates of primary DRG neurons
were prepared using the same lysis conditions. MDA-MB-231 cells were
stimulated with Sema 3A–Fc (1  g/ml) for 1 h and washed on ice with ice-
cold PBS. LiCl was applied at 20 mM for 30 min before the Sema 3A–Fc
was added. Cells were lysed in lysis buffer (10 mM Tris, pH 8, 0.25 su-
crose, 0.5% NP-40, 10 mM MgCl2, 0.1 mM DTT, protease and phos-
phatase inhibitors). After removing insoluble material by centrifugation,
protein concentration was determined using Bio-Rad Laboratories protein
assay, and protein extracts (40  g per lane) were separated by SDS-PAGE
(10%) and transferred onto nitrocellulose. Bound proteins were detected by
Western blotting. All primary antibodies were used at 1:1,000. Secondary
antibodies were purchased from Vector Laboratories and used at 1:5,000.
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